Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Histide AG. (11/10/14). "Press Release: Histide Raises CHF 4.5 M (USD 4.6 M) Series A Investment Round to Advance Its Pioneering Recoding Therapeutics Technology". Schindellegi.

Organisations Organisation Histitde AG
  Organisation 2 Parter Capital Group AG
Products Product Recoding Therapeutics™
  Product 2 private equity
Index term Index term Histide–SEVERAL: investment, 201411 financing round Series A CHF4.5m ($4.6m) led by Parter Capital + private investors
Persons Person Kemmerich, Florian (Histide AG 201411 CEO + Partner Life Science at Parter Capital Group)
  Person 2 Terhorst, Rüdiger G. (Parter Capital 201411)
     


Histide AG, a privately held Swiss biotech company pioneering a new class of non-mutagenic extracellular technology, Recoding TherapeuticsTM, has announced today the closure of a series A financing round of CHF 4.5 Million to expand further its IP licensing pipeline and clinical development of its innovative Recoding MoleculesTM. The round was led by PARTER Capital Group AG, Switzerland, and a group of private investors.

Florian Kemmerich, CEO of Histide and Partner, Life Science, at PARTER Capital Group said: “We are extremely pleased to achieve this important milestone for the Series A financing of Histide. We are excited about the potential of our Recoding Therapeutics™ platform and the extensive IP protection that we have secured around this ground-breaking approach to addressing disease.”

Histide was founded in 2014 by a team of experienced biotech scientists and business development experts to provide enhanced therapeutic solutions towards patients’ healing and quality of life.

Histide has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells. The new investment will be used to address new diseases and to further continue screening of the Recoding MoleculesTM and microenvironments in in vivo models.

Dr. Rüdiger G. Terhorst of PARTER Capital Group commented: “Histide is a unique and very promising investment for PARTER Capital Group in the life science industry. Our shareholders and investors have a long-term history as entrepreneurs and are highly committed to support the innovative scientific solutions Histide is currently developing to modify the way diseases are treated today.”


ENDS


Notes for editors:


About Histide

Histide AG is pioneering Recoding Therapeutics™, a novel therapy using non-mutagenic extracellular technologies to direct cell fate. Based on the universal understanding of the mechanisms underlying mammalian cell behavior, Histide™ has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells. In contrast to previously developed gene therapies or RNA based therapies, the Histide™ technology has the major advantage of not requiring the introduction of foreign molecules inside the cell which in turn may be irreversibly harmful to its functioning. Recoding Therapeutics™ are instead an extracellular technological approach that promotes and stimulates the cell’s natural capacities to redirect its own fate by integrating accurate micro-environmental recoding signals. This allows for a precise and fine functional tuning that offers a master control over the cell biology. Recoding Therapeutics™ are the closest to the natural cell physiology, hence, providing significantly improved safety and efficacy. They have the potential to address a wide range of altered cell conditions and diseases through the regeneration of a large majority of the human body tissues. Histide™ has created a broad and disruptive intellectual property portfolio including Recoding Molecules™, Micro-environmental Design and Therapeutical Development being a technological break-through with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics. Based in Europe, Histide™ has developed strong international collaborations with leading Universities and Institutes around the globe in order to make its expertise and technology known and promote the Recoding Therapeutics™.

For more information please also check the company website: www.histide.com


About PARTER Capital Group

PARTER Capital Group is a Private Equity House with focus on investments in special situations like spin-off or research based investments. As the successor of a Management Consulting Firm, PARTER Capital Group acts since many years as a trustful and discrete partner of large industrial conglomerates and banks in the case of R&D based projects.

Since several years PARTER Capital Group is engaged in high-tech markets and has a strategic focus on biotech and medtech acquisition projects. For more information please also check the company website: www.parter-capital.de


Contacts

At Histide AG
Dr Veronika Gocheva
+33 6 70 93 75 93
contact@histide.com

or

At Instinctif Partners
Dr Lynne Trowbridge/Dr Robert Mayer
+44 20 7457 2861 / +49 89 3090 5189 13
histide@instinctif.com

   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px




» top